Tango Therapeutics, Inc.
TNGX
$1.21
-$0.06-4.72%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.12M | 11.61M | 19.88M | 6.47M | 5.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.12M | 11.61M | 19.88M | 6.47M | 5.43M |
| Cost of Revenue | 33.94M | 33.26M | 38.65M | 38.07M | 31.34M |
| Gross Profit | -29.82M | -21.66M | -18.78M | -31.59M | -25.91M |
| SG&A Expenses | 11.09M | 11.22M | 10.77M | 10.66M | 9.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.03M | 44.49M | 49.43M | 48.73M | 40.44M |
| Operating Income | -40.91M | -32.88M | -29.55M | -42.26M | -35.01M |
| Income Before Tax | -37.62M | -29.11M | -25.49M | -37.87M | -30.72M |
| Income Tax Expenses | 49.00K | 54.00K | 65.00K | 40.00K | 47.00K |
| Earnings from Continuing Operations | -37.67M | -29.17M | -25.55M | -37.91M | -30.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.67M | -29.17M | -25.55M | -37.91M | -30.76M |
| EBIT | -40.91M | -32.88M | -29.55M | -42.26M | -35.01M |
| EBITDA | -40.29M | -32.26M | -28.92M | -41.63M | -34.40M |
| EPS Basic | -0.35 | -0.27 | -0.24 | -0.35 | -0.32 |
| Normalized Basic EPS | -0.19 | -0.17 | -0.15 | -0.22 | -0.19 |
| EPS Diluted | -0.35 | -0.27 | -0.24 | -0.35 | -0.32 |
| Normalized Diluted EPS | -0.19 | -0.17 | -0.15 | -0.22 | -0.19 |
| Average Basic Shares Outstanding | 108.68M | 108.51M | 108.31M | 108.17M | 97.22M |
| Average Diluted Shares Outstanding | 108.68M | 108.51M | 108.31M | 108.17M | 97.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
